Drug interactions
Orphenadrin + Ruxolitinib
Severity: Minor
Orphenadrin and Ruxolitinib: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Orphenadrine is described as a weak CYP3A4 inhibitor, while ruxolitinib is metabolized mainly by CYP3A4. Any increase in ruxolitinib exposure is expected to be small and is unlikely to be clinically important.
What this interaction means in plain words
Orphenadrin and Ruxolitinib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Orphenadrin belongs to Musculoskeletal; Ruxolitinib belongs to Oncology.
Why it happens
Possible weak inhibition of CYP3A4-mediated ruxolitinib metabolism.
What to do
No dose change is usually needed. Monitor blood counts as routinely required during ruxolitinib therapy.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Orphenadrin and Ruxolitinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Orphenadrin
Other interactions of Ruxolitinib
Frequently asked questions
Can I take Orphenadrin with Ruxolitinib?
MediHelp rates the interaction as minor. Orphenadrin and Ruxolitinib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Orphenadrine is described as a weak CYP3A4 inhibitor, while ruxolitinib is metabolized mainly by CYP3A4. Any increase in ruxolitinib exposure is expected to be small and is unlikely to be clinically important.
How serious is the interaction between Orphenadrin and Ruxolitinib?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No dose change is usually needed. Monitor blood counts as routinely required during ruxolitinib therapy.
What other medicines interact with Orphenadrin?
MediHelp also lists interactions of Orphenadrin with, for example, Alfentanil, Amobarbital, Benzhydrocodone / acetaminophen. The full list is on the Orphenadrin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
